Brief: ADC Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Zynlonta® (Loncastuximab Tesirine-Lpyl) In Combination With Rituximab In First-Line Diffuse Large B-Cell Lymphoma
20/07/2022 12:59
July 20 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2
CLINICAL TRIAL OF ZYNLONTA® (LONCASTUXIMAB TESIRINE-LPYL) IN
COMBINATION WITH RITUXIMAB IN FIRST-LINE DIFFUSE LARGE B-CELL
LYMPHOMA
Source text for Eikon: ID:nBw2Dr4dZa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million